Stress, Dietary Lapse and Weight Loss Among Adults With Type 2 Diabetes
NCT ID: NCT00831194
Last Updated: 2012-08-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
70 participants
INTERVENTIONAL
2009-03-31
2012-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Development of an Adaptive Treatment for Weight Loss in People With Prediabetes
NCT04745572
Improving Appetite Self-Regulation in African American Adults With Type 2 Diabetes
NCT05741125
Can Food Timing Reduce Your Diabetes Risk?
NCT05862818
Metabolic Impact of Time Restricted Feeding
NCT03129581
Study of Time-restricted Eating on Weight Loss.
NCT03393195
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
HEALTH_SERVICES_RESEARCH
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diet plan and PDA
Personalized diet plan and PDA self reporting.
Participants will be given personalized diet plan with a 0.5- 1 lb weight loss/week, based on each person's goals. He/she will also be prompted by a pre programmed PDA to enter dietary lapses and stress inducing events. Saliva samples will be collected as per the study plan.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Personalized diet plan and PDA self reporting.
Participants will be given personalized diet plan with a 0.5- 1 lb weight loss/week, based on each person's goals. He/she will also be prompted by a pre programmed PDA to enter dietary lapses and stress inducing events. Saliva samples will be collected as per the study plan.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Type 2 diabetes diagnosis by American Diabetes Association standard criteria. (Confirmed by physician's note or blood glucose reports in previous year or Prescriptions for medications to control blood glucose dated in participant's name within last year).
* BMI \> 30 kg/m2.
Exclusion Criteria
* Cognitive impairment severe enough to preclude informed consent or valid self report.
* Use of medications that significantly affect appetite.
* Eating disorder.
* Inability or unwillingness to use PDA for 6 months.
* Inability or unwillingness to collect saliva samples.
21 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Johns Hopkins Bloomberg School of Public Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lawrence J. Cheskin
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lawrence J Cheskin, MD
Role: PRINCIPAL_INVESTIGATOR
Johns Hopkins Bloomberg School of Public Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johns Hopkins Bloomberg School of Public Health
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB#00001685
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.